Karyopharm to Report Second Quarter 2024 Financial Results on August 6, 2024

Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company focused on novel cancer therapies, has announced it will report its second quarter 2024 financial results on Tuesday, August 6, 2024.

Rhea-AI Summary

Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company focused on novel cancer therapies, has announced it will report its second quarter 2024 financial results on Tuesday, August 6, 2024. The company's management team will host a conference call and audio webcast at 8:00 a.m. ET on the same day to discuss the financial results and provide company updates.

Investors and interested parties can access the conference call by dialing (800) 836-8184 (local) or (646) 357-8785 (international) at least 10 minutes before the start time. A live audio webcast of the call, along with accompanying slides, will be available on the company's website under the 'Events & Presentations' section. An archived version of the webcast will be accessible approximately two hours after the event.

Argus Session date unavailable

-6.58% session move Open Argus

Details

News Market Reaction – KPTI

The recorded move for KPTI in the trading session of this news was -6.58%.

Data tracked by StockTitan Argus. Session date unavailable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

-- Conference Call Scheduled for Tuesday, August 6, 2024, at 8:00 a.m. ET --

NEWTON, Mass., July 31, 2024 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced it will report second quarter 2024 financial results on Tuesday, August 6, 2024. Karyopharm's management team will host a conference call and audio webcast at 8:00 a.m. ET on Tuesday, August 6, 2024, to discuss the financial results and other company updates.

To access the conference call, please dial (800) 836-8184 (local) or (646) 357-8785 (international) at least 10 minutes prior to the start time and ask to be joined into the Karyopharm Therapeutics call. A live audio webcast of the call, along with accompanying slides, will be available under "Events & Presentations" in the Investor section of the Company's website, http://investors.karyopharm.com/events-presentations. An archived webcast will be available on the Company's website approximately two hours after the event.

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is a commercial-stage pharmaceutical company whose dedication to pioneering novel cancer therapies is fueled by a belief in the extraordinary strength and courage of patients with cancer. Since its founding, Karyopharm has been an industry leader in oral compounds that address nuclear export dysregulation, a fundamental mechanism of oncogenesis. Karyopharm's lead compound and first­in­class, oral exportin 1 (XPO1) inhibitor, XPOVIO^® (selinexor), is approved in the U.S. and marketed by the Company in three oncology indications. It has also received regulatory approvals in various indications in a growing number of ex­U.S. territories and countries, including Europe and the United Kingdom (as NEXPOVIO^®) and China. Karyopharm has a focused pipeline targeting indications in multiple high unmet need cancers, including in multiple myeloma, endometrial cancer, myelofibrosis, and diffuse large B-cell lymphoma (DLBCL). For more information about our people, science and pipeline, please visit www.karyopharm.com, and follow us on LinkedIn and on X at @Karyopharm.

XPOVIO^® and NEXPOVIO^® are registered trademarks of Karyopharm Therapeutics Inc. Any other trademarks referred to in this release are the property of their respective owners.

View original content to download multimedia:https://www.prnewswire.com/news-releases/karyopharm-to-report-second-quarter-2024-financial-results-on-august-6-2024-302211523.html

SOURCE Karyopharm Therapeutics Inc.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Karyopharm Therapeutics (KPTI) report its Q2 2024 financial results?

Karyopharm Therapeutics (KPTI) will report its second quarter 2024 financial results on Tuesday, August 6, 2024.

What time is Karyopharm's (KPTI) Q2 2024 earnings call scheduled for?

Karyopharm's (KPTI) Q2 2024 earnings call is scheduled for Tuesday, August 6, 2024, at 8:00 a.m. ET.

How can investors access Karyopharm's (KPTI) Q2 2024 earnings call?

Investors can access Karyopharm's (KPTI) Q2 2024 earnings call by dialing (800) 836-8184 (local) or (646) 357-8785 (international), or by joining the live audio webcast available on the company's website.

Where can I find the slides for Karyopharm's (KPTI) Q2 2024 earnings presentation?

The slides for Karyopharm's (KPTI) Q2 2024 earnings presentation will be available under the 'Events & Presentations' section in the Investor area of the company's website.